Cas:295349-63-2 tert-butyl 2-morpholin-4-ylpyridine-4-carboxylate manufacturer & supplier

Chemical Name:tert-butyl 2-morpholin-4-ylpyridine-4-carboxylate

CAS.NO:295349-63-2

Synonyms:t-butyl 2-morpholinoisonicotinate;tert-butyl 2-morpholinopyridine-4-carboxylate

Molecular Formula:C₁₄H₂₀N₂O₃

Molecular Weight:264.32000

HS Code:

Physical and Chemical Properties:

Melting point:N/A

Boiling point:411.4ºC at 760mmHg

Density:1.132g/cm3

Index of Refraction:1.527

PSA:51.66000

Exact Mass:264.14700

LogP:1.93850

Material Safety Information (Applicable for Hazard Chemicals)

RIDADR:

Packing Group:

Contact us for information like t-butyl 2-morpholinoisonicotinate chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,tert-butyl 2-morpholinopyridine-4-carboxylate physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,t-butyl 2-morpholinoisonicotinate Use and application,tert-butyl 2-morpholinopyridine-4-carboxylate technical grade,usp/ep/jp grade.

Related News: Catalent, a global leader in clinical supply services, recently announced the launch of its new CTSuccessTM clinical trial planning service, designed to support trial sponsors with earlier, more proactive and robust clinical supply chain planning, and reduce the risk of delays and budget overspend common to clinical trials as they progress. tert-butyl 2-morpholin-4-ylpyridine-4-carboxylate manufacturer In the first round of nationwide implement of the program, in September, multinationals including Sanofi and Eli Lilly managed to cut some prices low enough to levels close to those offered by local generic makers. tert-butyl 2-morpholin-4-ylpyridine-4-carboxylate supplier Catalent, a global leader in clinical supply services, recently announced the launch of its new CTSuccessTM clinical trial planning service, designed to support trial sponsors with earlier, more proactive and robust clinical supply chain planning, and reduce the risk of delays and budget overspend common to clinical trials as they progress. tert-butyl 2-morpholin-4-ylpyridine-4-carboxylate vendor In the first round of nationwide implement of the program, in September, multinationals including Sanofi and Eli Lilly managed to cut some prices low enough to levels close to those offered by local generic makers. tert-butyl 2-morpholin-4-ylpyridine-4-carboxylate factory “The synergies among our Regulatory, Clinical and Real-World Evidence (RWE) practices and CROS NT’s global biometrics capabilities will enhance Alira Health’s unique ability to serve clients across their solutions lifecycle,” said CEO Gabriele Brambilla in a statement.